drugset / Trial / NCT06221059

Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease

NCT06221059

Phase 2 Completed 181 enrolled Shandong Suncadia Medicine Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study was to evaluate the efficacy of HRS-1780 tablets or Henagliflozin Proline tablets in patients with chronic kidney disease by evaluating UACR change from baseline to Week 13

Timeline

Start
2024-03-02
Primary completion
2025-03-05
Completion
2025-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-1780 Small molecule
Subject Henagliflozin Proline Unknown